MedTrace Logo

Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients.

NCT05740150 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 462

Last updated 2023-02-22

No results posted yet for this study

Summary

The goal of this assessor blinded randomized controlled trial is to compare a lock solution containing taurolidine, citrate and heparin to a heparin only lock solution for the prevention of central line associated bloodstream infections in paediatric oncology patients with a central venous access device.

Conditions

  • Central Line-associated Bloodstream Infection (CLABSI)

Interventions

DEVICE

TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)

The TauroLock-Hep100 is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.

DEVICE

Heparin lock (heparin 100 IU/mL)

The Heparin lock is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.

Sponsors & Collaborators

  • Dutch Cancer Society

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • Princess Maxima Center for Pediatric Oncology

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
0 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-27
Primary Completion
2023-12-01
Completion
2023-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05740150 on ClinicalTrials.gov